This website is intended for healthcare professionals only.
BRIDGE
An exclusive knowledge hub for HCPs worldwide
hear from internationally renowned leukemia experts as they share clinical insights from daily practice and industry research.
Bridge Webinars On-Demand
First-line Treatment of Children with ALL and Management of Aspararginase —Associated Hypersensitivity — Insights from the US
First-line treatment of children ALL and management of asparaginase-associated hypersensitivity
Pediatric and pediatric-inspired regimens in AYA/adult patients with ALL: Efficacy, safety and practical insights – A US perspective
Benefits and limitations of pediatric-inspired regimens and the most common toxicity in adults
A clinical perspective on premedication and therapeutic drug monitoring (TDM) in the ALL AIEOP-BFM trials
Why is therapeutic drug (TDM) important and how feasible is it in clinical practice?
Treatment of AYA/adult patients
with ALL: focus on the role of asparaginase
Treating adolescents and young adults with ALL and the central role of asparginase
Taking aim IDH1 mutations to improve outcomes in AML
Treating mIDH1 patients who are ineligible for intensive chemotherapy
How to test for, and treat, mIDH1 aml in patients’ ineligible for intensive chemotherapy: from laboratory to clinical practice
InspirationALL is now BRIDGE Leukemias
The InspirationALL program has now become BRIDGE Leukemias, where we will continue to bring together ALL and AML experts to discuss key topics within these indications and start a bridge of discussions between HCPs around the world. Stay tuned with us!